Alnylam Pharmaceuticals I... (ALNY)

NASDAQ: ALNY · Real-Time Price · USD

257.63

-5.61 (-2.13%)

At close: May 01, 2025, 12:32 PM

-2.13% (1D)

Bid	240.31
Market Cap	33.51B
Revenue (ttm)	2.25B
Net Income (ttm)	-278.16M
EPS (ttm)	-2.18
PE Ratio (ttm)	-118.18
Forward PE	176.7
Analyst	Buy

Ask	279.93
Volume	599,854
Avg. Volume (20D)	920,268
Open	257.50
Previous Close	263.24
Day's Range	247.74 - 265.91
52-Week Range	144.73 - 304.39
Beta	0.30

About ALNY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection f...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 1, 2004

Employees 2,230

Stock Exchange NASDAQ

Ticker Symbol ALNY

Website https://www.alnylam.com

Full Company Profile

Analyst Forecast

According to 24 analyst ratings, the average rating for ALNY stock is "Buy." The 12-month stock price forecast is $322.5, which is an increase of 25.18% from the latest price.

Stock Forecasts

Earnings Surprise

New

Alnylam Pharmaceuticals has released their quartely earnings on May 1, 2025:

Revenue of $594.19M exceeds estimates by $8.37M, with 20.20% YoY growth.

EPS of -0.01 exceeds estimates by 1.02, with 93.75% YoY growth.

Next Earnings Release

Alnylam Pharmaceuticals Inc. is scheduled to release its earnings on May 1, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+2.6%

Alnylam Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription

1 month ago

+11.75%

Alnylam Pharmaceuticals shares are trading higher after the company secured FDA approval pf sNDA for its RNAi therapeutic, AMVUTTRA ,for treatment of ATTR-CM in adults.

News

5 hours ago · zacks.com

Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare t...

Just now · zacks.com

Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.16 per share a year ago.

1 day ago · zacks.com

Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Evaluate the expected performance of Alnylam (ALNY) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics fo...

2 days ago · businesswire.com

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for...

1 week ago · zacks.com

Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago · businesswire.com

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter endi...

2 weeks ago · zacks.com

Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last?

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in ...

4 weeks ago · businesswire.com

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 2...

1 month ago · businesswire.com

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HEL...

1 month ago · businesswire.com

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (F...

Load More News